What price is associated with the 308-share grant reported by Casey Tansey for INSP?

The 308-share grant is reported at $52.07 per share. This figure reflects the reference price used for valuing the stock received in lieu of cash director fees under the company’s Non-Employee Director Compensation Policy.

Inspire Medical director granted 308 shares

Tansey Casey M reported acquisition or exercise transactions in this Form 4 filing.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Tansey Casey M reported acquisition or exercise transactions in this Form 4 filing.

Inspire Medical Systems director Casey M. Tansey received a grant of 308 shares of Common Stock on April 15, 2026, as stock compensation in lieu of cash fees under the company’s Non-Employee Director Compensation Policy, at a reference price of $52.07 per share.

Following this award, Tansey directly holds 22,724 shares. Additional shares are reported as held indirectly through two family irrevocable trusts, each holding 500 shares of Common Stock.

Insider Trade Summary

Grant/Award: 308 shares

Grant/Award 3 txns

Insider Tansey Casey M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	308	$52.07	$16K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 22,724 shares (Direct); Common Stock — 1,000 shares (Indirect, By Family Trust)

Footnotes (3)

F1. Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy.
F2. Securities held by The Kimberly Tansey Irrevocable Trust.
F3. Securities held by The Kylie Tansey Irrevocable Trust.

Key Figures

Stock grant size: 308 shares Grant reference price: $52.07 per share Direct holdings after grant: 22,724 shares +2 more

5 metrics

Stock grant size 308 shares Common Stock grant on April 15, 2026

Grant reference price $52.07 per share Value of shares received in lieu of cash fees

Direct holdings after grant 22,724 shares Common Stock directly owned following the transaction

Kimberly Tansey Trust holdings 500 shares Common Stock held by The Kimberly Tansey Irrevocable Trust

Kylie Tansey Trust holdings 500 shares Common Stock held by The Kylie Tansey Irrevocable Trust

Key Terms

Non-Employee Director Compensation Policy, Irrevocable Trust, Common Stock

3 terms

Non-Employee Director Compensation Policy financial

"received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy"

Irrevocable Trust financial

"Securities held by The Kimberly Tansey Irrevocable Trust."

An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.

Common Stock financial

"Represents shares of common stock received in lieu of cash fees"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Inspire Medical Systems (INSP) director Casey Tansey report on this Form 4?

Director Casey M. Tansey reported receiving 308 shares of Inspire Medical Systems common stock as a stock grant. The shares were received instead of cash fees under the company’s Non-Employee Director Compensation Policy on April 15, 2026.

Was the Casey Tansey Form 4 for INSP a stock purchase or a grant?

The Form 4 reflects a stock grant, not an open-market purchase. Tansey acquired 308 shares of common stock as a grant in lieu of cash fees, consistent with the company’s Non-Employee Director Compensation Policy.

How many Inspire Medical Systems shares does Casey Tansey hold after this transaction?

After the grant, Casey Tansey directly holds 22,724 shares of Inspire Medical Systems common stock. The filing also reports 500 shares held by The Kimberly Tansey Irrevocable Trust and 500 shares held by The Kylie Tansey Irrevocable Trust.

How are family trust holdings disclosed in Casey Tansey’s INSP Form 4?

The Form 4 notes that certain securities are held by The Kimberly Tansey Irrevocable Trust and The Kylie Tansey Irrevocable Trust. Each trust is reported as holding 500 shares of Inspire Medical Systems common stock as indirect ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/16/2026 - 04:05 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tansey Casey M

(Last)

(First)

(Middle)

C/O INSPIRE MEDICAL SYSTEMS, INC.

5500 WAYZATA BLVD., SUITE 1600

(Street)

GOLDEN VALLEY

MINNESOTA

55416

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Inspire Medical Systems, Inc. [ INSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/15/2026		A		308⁽¹⁾	A	$52.07	22,724	D
Common Stock								500	I	By Family Trust⁽²⁾
Common Stock								500	I	By Family Trust⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy.

2. Securities held by The Kimberly Tansey Irrevocable Trust.

3. Securities held by The Kylie Tansey Irrevocable Trust.

	/s/ Bryan Phillips, Attorney-in-Fact for Casey M. Tansey	04/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR